Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.

Analysts have recently evaluated Recursion Pharmaceuticals and provided 12-month price targets. The average target is $7.4, ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.72, moving +2.24% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.28%.

Find the latest on short interest, settlement dates, average share volume, and days to cover for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

LAS VEGAS (AP) — Rookie Sonia Citron scored 21 points, Sug Sutton added 17 and the short-handed Washington Mystics beat the Las Vegas Aces 94-83 on Thursday night for their third straight victory.

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Nootropics are drugs or supplements that may or may not boost brain function. Research is limited but here are the ones worth trying under the guidance of your medical professional.

As of July 1, 2025 (FY26) the IFC no longer supports ST contracts for individuals requiring an employment visa to work. In HQ, IFC ST contracts are limited to nationals, permanent residents, and ...